Zhongxin Online Hai, October 25 (Reporter Chen Jing) With the rising incidence and mortality of cardiovascular diseases, improving the cardiovascular chronic disease management system has become an urgent need.
The reporter learned on the 25th that at the "Leading Heart Future - Chronic Disease Management Ecosystem Forum", Professor Huo Yong, professor of cardiology at peking university first hospital, pointed out: "In the past decade, we have made certain achievements in this regard. The modern chest pain center system has gradually matured, becoming an important starting point for the cardiovascular prevention and treatment system, and the national acute chest pain collaborative treatment network is also strengthening. In the future, China's cardiovascular prevention and treatment work needs to pay close attention to key points such as blood lipids and antithrombotic management, and promote the construction of more discipline centers. ”
Professor Yuan Zuyi, president of the Cardiovascular Disease Hospital of the First Affiliated Hospital of Xi'an Jiaotong University, said bluntly that in recent years, innovative projects in the management of cardiovascular chronic diseases such as ACS (acute coronary syndrome) management, construction of chest pain centers, and diagnosis and treatment of atrial fibrillation have been continuously landed, which has broken through the perspective of previous diseases and gradually established a management system from prevention, diagnosis and treatment, treatment and rehabilitation. This change reflects the continuous standardization and science of the innovative concept of cardiovascular chronic disease life cycle management in practice.
It is reported that at the "Chuang LingXin Future - Chronic Disease Management Ecosystem Forum", a number of domestic front-line cardiovascular experts, officials, policy research experts and senior executives of medical and health enterprises shared innovative practices in cardiovascular chronic disease management in their respective fields, discussed the understanding of patient-centered cardiovascular chronic disease life cycle management, and looked forward to the future picture of the cardiovascular chronic disease management ecosystem. The forum attracted hundreds of thousands of people to watch online.
Professor Lu Yong, President of Luwan Branch of Ruijin Hospital affiliated to Shanghai Jiao Tong University, emphasized the importance of the construction of venous thromboembolism (VTE) prevention and treatment system in the hospital. He said: "With the rapid development of Internet medical technology, we can use the assistance of artificial intelligence to improve the early warning and identification of early diseases, and strengthen the follow-up management of patients through digital, automated and integrated platforms, thereby further consolidating the safety zone of patients." ”
Professor Li Yigang, Director of the Department of Cardiology of Shanghai Xinhua Hospital, said when sharing the integration of atrial fibrillation treatment: "The current disease load of atrial fibrillation is underestimated, and there is an urgent need for asymptomatic atrial fibrillation screening, and the promotion of wearable patches and wristband applications can improve the early screening rate; in the future, we look forward to the early introduction of innovative drugs with high risk-benefit ratio, fewer side effects and significant efficacy such as dronedarone hydrochloride tablets as soon as possible to make up for the lack of atrial fibrillation treatment drugs." The expert pointed out that more patients can receive minimally invasive interventions such as catheter ablation; and vigorously promote the construction of atrial fibrillation centers, implement graded diagnosis and treatment of atrial fibrillation, so that atrial fibrillation can be homogeneously diagnosed and treated, the whole process of standardized management, reduce stroke complications, improve quality of life and survival rate.
In the diagnosis and treatment of cardiovascular diseases, drug intervention is very important. In patients with acute coronary syndrome, for example, even after coronary intervention, there is still a high risk of recurrence within one year. During the interview, the reporter learned that the application of the new lipid-lowering drug PCSK9 inhibitor alioxeliumab can further reduce its risk of cardiovascular adverse events, and studies have confirmed that it is related to a 15% decrease in all-cause deaths. This product provides a new treatment option for patients with unsatisfactory anti-atherosclerosis treatment in China.
Clopidogrel aspirin tablets were recently approved for marketing by the State Drug Administration for the prevention of atherosclerotic thrombosis in adult patients with associated acute coronary syndrome. Liu Jing, general manager of Sanofi China's Innovation and Core Business Unit, said in an interview that in addition to bringing more drugs into China, the company has actively participated in the procurement of quantities, and the response policy has significantly reduced the prices of two classic drugs for cardiovascular diseases.
According to reports, in order to allow more patients to benefit from innovative drugs as soon as possible, relevant pharmaceutical companies are trying to cooperate with commercial insurance companies, hoping to reduce the burden of drug purchase for patients. Taking aliciclizumab as an example, shortly after it was approved for marketing, the insurance program for postoperative risk protection for high-risk patients with ACS was quickly "released".
Liu Jing said: "In the future, we will accelerate the introduction of innovative drugs into China, explore the implementation of omni-channel management, promote the expansion of treatment accessibility, and accelerate the transformation of digital business models and digital therapy cooperation to achieve efficiency and convenience." (End)
Source: China News Network